5 Most Undervalued Biotech Stocks to Buy According to Analysts

Page 5 of 5

1. Cullinan Oncology, Inc. (NASDAQ:CGEM)

Upside Potential as of August 14: 146.34%

PE Ratio (TTM) as of August 14: 8.87

Number of Hedge Fund Holders: 22

Cambridge, Massachusetts-based Cullinan Oncology, Inc. (NASDAQ:CGEM) is a  biopharmaceutical company focused on modality-agnostic targeted oncology therapies.

On August 11, HC Wainwright & Co. lowered the price target on Cullinan Oncology, Inc. (NASDAQ:CGEM) shares to $34 from $39 and maintained a ‘Buy’ rating for the shares. The price target represents an upside potential of 202.44% based on the share price on August 14.

Cullinan Oncology, Inc. (NASDAQ:CGEM) ranks #1 on our list of 11 most undervalued biotech stocks to buy according to analysts based on its TTM PE ratio of 8.87 and the highest upside potential on its share price according to the average analyst price targets. The shares of the company were also widely owned by hedge funds, as of Q2 2023, with 22 prominent hedge funds tracked by Insider Monkey holding its shares valued at $192 million.

You may also like to read 10 Stocks Getting a Huge Vote of Confidence From Wall Street Analysts and 12 Best Virtual Reality Stocks to Invest In

Page 5 of 5